A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)

Overview

This is a randomized, 2-part, 2-arm, open-label, parallel-group, multi-center study to compare the PK of etrolizumab administered subcutaneously by an AI (test device) or a PFS-NSD (reference device) in healthy participants. The study will comprise a pilot cohort (Part 1) to estimate the geometric mean ratio (GMR) and variability of the maximum observed concentration (Cmax) and area under the concentration-time curve (AUC) to confirm or determine the sample size for the pivotal cohort (Part 2). The pivotal cohort will demonstrate exposure comparability of Cmax, AUC from Hour 0 to the last measurable concentration (AUClast), and AUC from Hour 0 to extrapolated infinite time (AUC0-inf), values for a single dose of etrolizumab administered subcutaneously either by the AI or the PFS-NSD.

Full Title of Study: “A Randomized, Open-Label, 2-Part, 2-Arm, Parallel-Group, Single-Dose, Multi-Center Study in Healthy Subjects to Investigate the Comparability of Pharmacokinetics of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device or an Auto-Injector”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Health Services Research
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 9, 2018

Interventions

  • Drug: Etrolizumab
    • Etrolizumab will be administered at a dose of 105 milligrams (mg).
  • Device: Auto-Injector (AI)
    • The pre-filled AI will be used to administer etrolizumab.
  • Device: Prefilled Syringe With Needle Safety Device (PFS-NSD)
    • The PFS-NSD will be used to administer etrolizumab.

Arms, Groups and Cohorts

  • Experimental: Part 1: Etrolizumab AI
    • Participants will receive a single dose of etrolizumab via subcutaneous (SC) injection using the AI on Day 1.
  • Active Comparator: Part 1: Etrolizumab PFS-NSD
    • Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
  • Experimental: Part 2: Etrolizumab AI
    • Participants will receive a single dose of etrolizumab via SC injection using the AI on Day 1.
  • Active Comparator: Part 2: Etrolizumab PFS-NSD
    • Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.

Clinical Trial Outcome Measures

Primary Measures

  • Part 1: Cmax of Etrolizumab
    • Time Frame: Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)
  • Part 1: AUClast of Etrolizumab
    • Time Frame: Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)
  • Part 1: AUC0-inf of Etrolizumab
    • Time Frame: Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)
  • Part 1: Ratio of AUClast to AUC0-inf (AUCR) of Etrolizumab
    • Time Frame: Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)
  • Part 2: Cmax of Etrolizumab
    • Time Frame: Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)
  • Part 2: AUClast of Etrolizumab
    • Time Frame: Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)
  • Part 2: AUC0-inf of Etrolizumab
    • Time Frame: Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)

Secondary Measures

  • Part 1: Time to Maximum Observed Concentration (tmax) of Etrolizumab
    • Time Frame: Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)
  • Part 2: tmax of Etrolizumab
    • Time Frame: Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)
  • Part 1: Apparent Terminal Elimination Half-Life (t1/2) of Etrolizumab
    • Time Frame: Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)
  • Part 2: t1/2 of Etrolizumab
    • Time Frame: Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)
  • Part 2: AUCR of Etrolizumab
    • Time Frame: Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)
  • Percentage of Participants With Adverse Events
    • Time Frame: Part 1 and 2: Baseline up to Day 71
  • Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Etrolizumab
    • Time Frame: Part 1 and 2: Baseline up to Day 71

Participating in This Clinical Trial

Inclusion Criteria

  • Within the body weight range of 60 to 100 kilograms, inclusive (for the pivotal cohort [Part 2] only) – Within body mass index (BMI) range 18.0 to 30.0 kilograms per square meter (kg/m^2), inclusive – In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), and vital signs – Females will be non-pregnant, non-lactating, and either postmenopausal (at least 12 months of non-therapy-induced amenorrhea)/surgically sterile (e.g., tubal ligation, hysterectomy) for at least 90 days prior to enrolment, or agree to remain abstinent/use a highly effective method of contraception for at least 24 weeks after study drug administration – Males will either be sterile or agree to remain abstinent/use a highly effective method of contraception for at least 24 weeks after study drug administration. Male participants will refrain from sperm donation from Check-in (Day -1) until 24 weeks following study drug administration Exclusion Criteria:

  • Any prior treatment with etrolizumab or other anti-integrin agents (including natalizumab, vedolizumab, and efalizumab) – Any prior treatment with anti-mucosal addressin cell adhesion molecule 1 (anti-MAdCAM-1) agents – Any prior treatment with rituximab – Received intravenous corticosteroids within 30 days prior to Screening – Use of agents that deplete B or T cells (e.g., alemtuzumab, rituximab, or visilizumab) within 12 months prior to randomization – Any prior immunosuppressive agents (including cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil) – Chronic nonsteroidal anti-inflammatory drug (NSAID) use – Use of any prescription medications/products within 14 days prior to Check in (Day -1) – History of demyelinating disease – Neurological conditions or diseases – History of cancer – History of alcoholism or drug addiction within less than (<) 1 year prior to Screening – History of active or latent tuberculosis (TB), regardless of treatment history – History of recurrent opportunistic infections and/or history of severe disseminated viral infections – Positive for human immunodeficiency virus (HIV) antibody – Any current or recent signs or symptoms of infection – Pregnant or lactating – Hospitalized within 4 weeks prior to and during Screening – History of organ transplant – Presence of skin rash at Screening or history of other skin disorders – Tattoos, scars, chronic rashes, or sunburn in the area of the designated injection site

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Genentech, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Clinical Trials, Study Director, Hoffmann-La Roche

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.